Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Acurx Pharmaceuticals Trading Up 0.6 %
Shares of NASDAQ ACXP opened at $0.46 on Monday. The stock has a market capitalization of $9.04 million, a PE ratio of -0.42 and a beta of -1.71. The stock’s fifty day simple moving average is $0.73 and its two-hundred day simple moving average is $1.29. Acurx Pharmaceuticals has a 12-month low of $0.43 and a 12-month high of $3.33.
Insider Buying and Selling
In other Acurx Pharmaceuticals news, CEO David P. Luci purchased 49,261 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was purchased at an average price of $1.01 per share, for a total transaction of $49,753.61. Following the purchase, the chief executive officer now directly owns 1,097,458 shares in the company, valued at approximately $1,108,432.58. This trade represents a 4.70 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 29.60% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Check Out Our Latest Research Report on Acurx Pharmaceuticals
Acurx Pharmaceuticals Company Profile
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
See Also
- Five stocks we like better than Acurx Pharmaceuticals
- What Does Downgrade Mean in Investing?
- How to Build the Ultimate Everything ETF Portfolio
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is the Euro STOXX 50 Index?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.